GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » US Stem Cell Inc (OTCPK:USRM) » Definitions » Shiller PE Ratio

US Stem Cell (US Stem Cell) Shiller PE Ratio : (As of Jun. 08, 2024)


View and export this data going back to 2008. Start your Free Trial

What is US Stem Cell Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


US Stem Cell Shiller PE Ratio Historical Data

The historical data trend for US Stem Cell's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Stem Cell Shiller PE Ratio Chart

US Stem Cell Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

US Stem Cell Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of US Stem Cell's Shiller PE Ratio

For the Biotechnology subindustry, US Stem Cell's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


US Stem Cell's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, US Stem Cell's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where US Stem Cell's Shiller PE Ratio falls into.



US Stem Cell Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

US Stem Cell's E10 for the quarter that ended in Dec. 2022 is calculated as:

For example, US Stem Cell's adjusted earnings per share data for the three months ended in Dec. 2022 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2022 (Change)*Current CPI (Dec. 2022)
=-0.001/125.2218*125.2218
=-0.001

Current CPI (Dec. 2022) = 125.2218.

US Stem Cell Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201303 -3.000 98.209 -3.825
201306 -3.000 98.518 -3.813
201309 -5.000 98.790 -6.338
201312 -1.000 98.326 -1.274
201403 1.000 99.695 1.256
201406 -1.000 100.560 -1.245
201409 -2.800 100.428 -3.491
201412 -1.910 99.070 -2.414
201503 -1.670 99.621 -2.099
201506 0.950 100.684 1.182
201509 -0.150 100.392 -0.187
201512 -0.786 99.792 -0.986
201603 -0.180 100.470 -0.224
201606 -0.060 101.688 -0.074
201609 -0.090 101.861 -0.111
201612 0.003 101.863 0.004
201703 -0.010 102.862 -0.012
201706 -0.001 103.349 -0.001
201709 -0.003 104.136 -0.004
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 -0.003 106.317 -0.004
201809 -0.001 106.507 -0.001
201812 -0.005 105.998 -0.006
201903 -0.002 107.251 -0.002
201906 -0.002 108.070 -0.002
201909 -0.004 108.329 -0.005
201912 0.000 108.420 0.000
202003 -0.001 108.902 -0.001
202006 -0.001 108.767 -0.001
202009 -0.003 109.815 -0.003
202012 0.000 109.897 0.000
202103 -0.002 111.754 -0.002
202106 -0.002 114.631 -0.002
202109 -0.001 115.734 -0.001
202112 0.000 117.630 0.000
202203 -0.002 121.301 -0.002
202206 -0.001 125.017 -0.001
202209 -0.001 125.227 -0.001
202212 -0.001 125.222 -0.001

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


US Stem Cell  (OTCPK:USRM) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


US Stem Cell Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of US Stem Cell's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


US Stem Cell (US Stem Cell) Business Description

Traded in Other Exchanges
N/A
Address
1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Executives
Murphy William P Jr director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Gregory Knutson director 14855 ABERDEN STREET NE, HAM LAKE MN 55304
Mark P Borman director 5240 WASHBURN AVENUE SOUTH, MINNEAPOLIS MN 55410
Charles A Hart director 19345 RHINESTONE STREET NW, ANOKA MN 55303
Sheldon T. Anderson director 1121 CRANDON BLVD., APT. D-103, KEY BISCAYNE FL 33149
Kristin C Comella officer: Chief Science Officer 1310 LEEWARD WAY, WESTON FL 33327
A Jones Lee director 54 LOCKE LAKE RD, FRIDLEY MN 55432
Karl Groth director 1160 FIFTH AVENUE, SUITE 207, NEW YORK NY 10029
Matthew J Fendrich officer: Vice President,Sales&Marketing 482 PEACOCK LANE SOUTH, JUPITER FL 33458
Alan P Timmins director 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Bruce C Carson director 11850 COTTONWOOD STREET NW, COON RAPIDS MN 55448
Howard J Leonhardt director, 10 percent owner, officer: Executive Chairman & CTO 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Bromley R Scott officer: VP of Public Relations 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Richard Iii Spencer director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Mike Tomas director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325

US Stem Cell (US Stem Cell) Headlines